Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Age 18 - 80
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is looking at using new drugs (daratumumab and carfilzomib) with two other common drugs (pomalidomide and dexamethasone) to treat people with a type of cancer called multiple myeloma that has come back or didn't respond to previous treatments.
This study is looking at using new drugs (daratumumab and carfilzomib) with two other common drugs (pomalidomide and dexamethasone) to treat people with a type of cancer called multiple myeloma that has come back or didn't respond to previous treatments.
Third Opinion AI Generated Synopsis
Trial Summary
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of care drugs involved in this study are: * Dexamethasone * Pomalidomide
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of care drugs involved in this study are: * Dexamethasone * Pomalidomide
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
